Loading…
← CockpitCompetitor Analysis › LALPATHLAB.NS Dr. Lal PathLabsOpen in the cockpit ↗

Dr. Lal PathLabsLALPATHLAB.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Medical/Nursing Services

One of India's largest diagnostic chains, offering pathology and radiology testing through labs and collection centres nationwide.

≈ India's Quest Diagnostics/LabCorp equivalentMomentum strong 73
Mkt cap
$3.53B
US dollars, full cap
Free float
46%
of shares outstanding
$/day
$6.14M
20-day average traded
Fwd P/E
50.5×
forward earnings
ROIC−WACC
+24.3 pp
WACC 12.9%
Hurdle
+20 pp
Req g minus delivered
Next earnings
78 days
4 Feb 2027
Close · INR₹1,965
1D-0.8%
1W-3.1%
1M+6.6%
3M+3.4%
6M+15.4%
YTD+32.6%
1Y+27.6%
ATR %3.2%
Beta0.32
52w lowhigh5.5% off high

What Dr. Lal PathLabs does

One of India's largest diagnostic chains, offering pathology and radiology testing through labs and collection centres nationwide.

Collects samples at many small centres and routes them to a few large reference labs, so each test costs little to run and the network fills the labs; patients mostly pay out of pocket, with test prices set by the company, not by insurers. The Lal family, which founded it, remains the largest shareholder.

In one line: India's Quest Diagnostics/LabCorp equivalent.

Products and services

  • Pathology testing
  • Radiology/imaging
  • Wellness/health check packages

Customers

  • Retail patients
  • Hospitals/doctors (referral testing)
  • Corporate wellness clients

Where it sits in the supply chain

  • Healthcare services
  • Diagnostics/pathology
  • Lab testing & collection network

What could go right

  • Rising diagnostic test volumes in India
  • Preventive health check demand growth

What could go wrong

  • Pricing pressure/price caps by regulators
  • Intense competition from regional labs

Moat: narrow (brand, scale, distribution). Large pan-India network of labs and collection centres with strong brand trust in diagnostics.

Headquarters: New Delhi, India · Founded: 1949 · Employees: 6,200

Named competitors

Dr. Lal PathLabs at a glance

Size Dr. Lal PathLabs (LALPATHLAB.NS) is an India Health Care company (Medical/Nursing Services) with a market value of $3.53B, the 261st largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,965 on 18 Nov 2026.

Performance Over six months the shares gained 15.4%, against +28.9% for the median peer and +3.8% for the India market (cap-weighted) — 7th lowest of 20 in its peer set.

Growth Revenue grew 16.7% over the last twelve months (peer median +11.3%); the operating margin is 23.6% (peer median 8.2%).

Valuation It trades at 50.5× forward earnings against a peer median of 36.1× (7th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 24.3 points above its cost of capital (12.9% WACC).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026Peer median 130LALPATHLAB.NS 118
Six months, rebased to 100: Dr. Lal PathLabs against the median of its 20 peers (local-currency closes).

Dr. Lal PathLabs financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹30.3B₹27.6B₹24.6B₹22.3B₹20.2B
Revenue growth—+12%+11%+10%—
Gross profit₹13.0B₹10.9B₹9.81B₹11.8B₹7.31B
EBITDA₹8.94B₹7.95B₹7.08B₹6.20B₹4.98B
Net income₹5.83B₹5.05B₹4.87B₹3.58B₹2.39B
Free cash flown/a₹5.35B₹5.85B₹5.20B₹4.35B
Capital expendituren/a₹1.73B₹539M₹574M₹446M
Total debt₹2.33B₹1.99B₹1.57B₹2.47B₹4.19B

Quarterly statements and history in the cockpit →

Dr. Lal PathLabs competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-25%0%+25%ACHCMCOV-BHIMSBLLNOPCH002044MDLFSTAVAHCONAZTANEOAGARWALEYE603882SHLEMEISLALPATHLAB.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Dr. Lal PathLabs is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%50×100×ACHCMCOV-BBLLNOPCH002044MDLFSTAVAHRDNTALIF-BAZTANEOAGARWALEYE603882SHLLALPATHLAB.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Dr. Lal PathLabs is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%75%MCOV-BBLLN3774OPCH002044MDLFSTAVAHRDNTALIF-BAZTAAGARWALEYE603882SHLEMEISLALPATHLAB.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Dr. Lal PathLabs is the large dot.

Dr. Lal PathLabs competitors and peer comparison

Head to head with its named competitors (LALPATHLAB.NS vs METROPOLIS.NS vs VIJAYA.NS vs THYROCARE.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Dr. Lal PathLabs LALPATHLAB.NS$3.53B+15%+17%24%50.5×32.3%
Metropolis Healthcare METROPOLIS.NS$1.25B+11%+20%18%44.5×32.4%
Vijaya Diagnostic Centre VIJAYA.NS$1.69B+18%+24%32%63.0×40.4%
Thyrocare Technologies THYROCARE.NS$858M+7%+22%26%36.0×28.5%

How Dr. Lal PathLabs compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Dr. Lal PathLabs against its 20 peers (data as of 18 Nov 2026)
MeasureLALPATHLAB.NSPeer medianRank in peer set
1-month return+6.6%+1.8%9th highest of 21
6-month return+15.4%+28.9%7th lowest of 20
Distance from 52-week high-5.5%-12.9%5th highest of 21
Revenue growth (TTM)+16.7%+11.3%8th highest of 21
Operating margin23.6%8.2%highest of 21
Forward P/E50.5×36.1×7th most expensive of 18
Growth the price implies (Req g, 7 yrs)32.3%19.6%6th most demanding of 18
Growth delivered (Del g)+11.8%+13.2%9th lowest of 18
Hurdle (Req g minus delivered)+20.5 pp+2.9 pp3rd most demanding of 18
ROIC minus cost of capital+24.3 pp-1.6 pphighest of 21
EV / EBITDA35.4×13.9×3rd most expensive of 16
Net debt / EBITDA-1.5×2.8×3rd least indebted of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Dr. Lal PathLabs LALPATHLAB.NSIndia$3.53B+15%+17%24%50.5×32.3%+11.8%
Acadia Healthcare ACHCUnited States$3.49B+56%+4%10%18.6×n/an/a
Medicover MCOV-B.STSweden$3.87B+21%+3%7%36.1×19.6%+20.2%
Hims & Hers Health HIMSUnited States$4.00B-26%+30%-1%n/an/an/a
BillionToOne BLLNUnited States$4.37B+7%+72%10%115.3×22.8%+71.9%
Fameglow 3774.HKHong Kong$4.54Bn/a+36%11%n/a57.4%+48.4%
Option Care Health OPCHUnited States$4.75B+43%+4%6%15.7×2.0%+13.2%
Meinian Onehealth Healthcare 002044.SZChina$2.60B-27%-4%9%49.6×4.2%+5.7%
Pediatrix Medical MDUnited States$2.41B+37%+2%12%12.4×-4.4%+2.0%
Lifestance Health LFSTUnited States$5.24B+79%+23%6%51.8×33.4%+30.4%
Aveanna Healthcare AVAHUnited States$2.37B+41%+17%12%12.2×7.7%+10.2%
Concentra Group Holdings Parent CONUnited States$5.31B+65%+12%17%22.3×3.6%+7.9%
Addus HomeCare ADUSUnited States$2.25B+29%+12%11%16.2×4.0%+13.2%
RadNet RDNTUnited States$5.66B+32%+21%5%93.2×38.8%+13.7%
AddLife ALIF-B.STSweden$2.13B+15%+2%8%39.0×21.1%+14.6%
Azenta AZTAUnited States$2.03B+162%+5%-2%83.2×38.0%+3.9%
NeoGenomics NEOUnited States$1.98B+72%+11%-6%53.5×n/an/a
Dr. Agarwal's Health Care AGARWALEYE.NSIndia$1.86B+20%+26%15%77.1×43.0%+26.9%
Guangzhou Kingmed Diagnostics 603882.SSChina$1.86B+5%-3%7%29.9×5.4%-6.1%
Sonic Healthcare SHL.AXAustralia$6.87B+6%+14%9%17.4×9.1%+3.5%
Emeis EMEIS.PAFrance$1.78B-33%+4%3%n/a21.2%+8.5%

Questions

Who are Dr. Lal PathLabs's main competitors?
Named competitors: Metropolis Healthcare (METROPOLIS.NS), Vijaya Diagnostic Centre (VIJAYA.NS), Thyrocare Technologies (THYROCARE.NS). The cockpit's measured peer set (industry) also includes Acadia Healthcare (ACHC), Medicover (MCOV-B.ST), Hims & Hers Health (HIMS), BillionToOne (BLLN), Fameglow (3774.HK), Option Care Health (OPCH).
Is Dr. Lal PathLabs expensive compared with its peers?
On forward p/e it trades at 50.5× against a peer median of 36.1×, 7th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Dr. Lal PathLabs stock performed?
Over six months to 18 Nov 2026 the shares returned +15.4% against +28.9% for the median peer; over one year +27.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.